news
Your source for the latest content and news from Cortalix:
Cortalix will present at Festival of Biologics in Basel, Switzerland, 15-17 October 2024
Herman Steen, CEO of Cortalix, will present a poster "A Synthetic Single-domain Antibody Discovery Platform for the Selection of Radiopharmaceuticals for Novel Fibrosis Targets" at the Festival of Biologics, October 15-17, 2024 in Basel, Switzerland. You are cordially...
Cortalix will present at PepTalk San Diego, CA, January 13-16 2025
Herman Steen, CEO of Cortalix, will present on "Single-Domain Antibody-Based Radiopharmaceuticals for Novel Cancer Stroma Targets" at the 24th Annual PepTalk Summit US, January 13-16, 2025 in San Diego, CA. For more information about Cortalix: www.cortalix.com Contact...
Cortalix will present at TRP Berlin, Germany, 5 – 7 December 2023
Herman Steen, CEO of Cortalix, will present on "Novel Fibrosis Targets for Molecular Imaging of Fibrogenesis & Fibrotic Cancers" at the 5th Targeted Radiopharmaceuticals Summit EU 2023, December 5 - 7, 2023 in Berlin, Germany. For more information about Cortalix:...
Cortalix is awarded a EUROSTARS grant and joins the existing consortium on molecular diagnostic PET-imaging of colorectal cancer
Cortalix will join the existing consortium on a EUROSTARS grant of EUR 1.7 million for colorectal cancer molecular PET-imaging. EUROSTARS is a joint program of EUREKA and the European Commission, co-funded by the national budgets of 36 EUROSTARS Participating and...
Cortalix acquires patents and knowhow from BiOrion
Cortalix BV acquires patents and know-how from BiOrion on its single domain antibody platform and fibrogenesis biomarker radiopharmaceuticals. With these patents and know-how, Cortalix can continue to work on 2 active clinical programs around PET imaging of...